Lidocaïne Aguettant (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, stabilizing them in an inactivated state. By preventing sodium influx, it stops the initiation and propagation of action potentials, thereby interrupting nerve signal transmission and producing reversible sensory and, at higher concentrations, motor blockade in the targeted area.

The dose of Lidocaïne Aguettant is determined by the prescribing clinician based on the specific procedure, patient weight, and maximum safe limits. Dosing guidelines are provided in the product labeling, and the prescriber tailors the amount to achieve adequate anesthesia while minimizing toxicity.

Safety data for lidocaine hydrochloride in pregnancy and lactation are limited. It should be used only when the expected benefit outweighs potential risks to the fetus or infant. Clinicians should evaluate each case individually and consider alternative options when possible.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Lidocaine offers a rapid onset (1–3 minutes) and moderate duration (30–120 minutes) compared with longer‑acting agents such as bupivacaine, which have slower onset but prolonged effect. Its safety profile is well‑characterized, making it a common choice for short‑ to medium‑duration procedures, whereas bupivacaine is preferred when extended analgesia is required.

Lidocaïne Aguettant should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from direct light and moisture. Do not freeze. Inspect the vial for particulate matter or discoloration before use, and discard if any abnormalities are observed.

The product is administered by injection. For infiltration, the solution is injected directly into the tissue surrounding the surgical site. Intradermal use involves a shallow injection into the dermis for skin testing. Intravenous regional anesthesia requires placement of a tourniquet and slow injection of the solution into a limb’s venous system.

Serious risks include severe allergic reactions (anaphylaxis), cardiac arrhythmias such as ventricular tachycardia, methemoglobinemia leading to reduced oxygen delivery, and central nervous system toxicity manifesting as seizures or loss of consciousness. Prompt recognition and supportive management are essential if these events occur.

Patients with known hypersensitivity to lidocaine or other amide‑type local anesthetics should avoid this product. It is also contraindicated in individuals with severe heart block, uncontrolled arrhythmias, or significant hepatic impairment that could impair drug metabolism. Clinical judgment is required for use in pregnant or lactating women.